The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Patients with Advanced Solid Tumors who had Exhausted All Other Treatment Options and were PD-(L)1 Experienced Achieved Significant Tumor Volume Reductions and Prolonged Progression Free Survival ...

First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in ...

31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy for stage IB-IIIA non-small cell lung cancer ... stage IIA to IIIB NSCLC cases. Bladder cancer hopes back on track There ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...

Good afternoon, everyone. Thank you for standing by. Welcome to CytomX Therapeutics third quarter, 2024 Financial results call. Please be advised that today's call is being recorded. I would now like ...

Sep. 11, 2024 — A team of doctors and researchers have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never ... Immune Cells Prevent Lung ...

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

Good morning, and welcome to Y-mAbs Therapeutics Inc. Third Quarter Conference Call for 2024. At this time, all participants are in a listen-only mode. Instruction for the question-and-answer session ...